<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558961</url>
  </required_header>
  <id_info>
    <org_study_id>CR0506PI</org_study_id>
    <secondary_id>REC:05-054</secondary_id>
    <nct_id>NCT00558961</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients</brief_title>
  <acronym>GL-CLB-001</acronym>
  <official_title>A Phase I-II Trial of Gleevec (Imatinib Mesylate) in Combination With Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia (CLL) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine maximum tolerated dose of Gleevec in combination
      with Chlorambucil in previously treated CLL patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A recent study by Aloyz et al demonstrated a synergistic effect of imatinib on
      chlorambucil-mediated cytotoxicity in CLL cells in vitro. Imatinib inhibits c-abl and
      sensitizes cells to chlorambucil. The Phase I component of the study will determine the
      maximum tolerated dose and recommended Phase II dose of Gleevec when used in combination with
      chlorambucil. Once the maximum tolerated dose has been determined, a total of 16 patients
      will be enrolled in the Phase II component of the study. This study will determine the dose
      limiting toxicities, pharmacokinetics and pharmacodynamics of Gleevec in combination with
      chlorambucil.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unsatisfactory enrollment
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure number of patients at maximum tolerated dose of Gleevec in combination with chlorambucil</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Report adverse events as a measure of safety</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Report response to treatment as a measure of efficacy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Report level of gleevec concentration at different doses as a measure of pharmacokinetics</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gleevec Chlorambucil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec and Chlorambucil</intervention_name>
    <description>The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Gleevec (imatinib mesylate)</other_name>
    <other_name>Chlorambucil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  B-cell chronic lymphocytic leukemia (a) Rai stage 0-II with indication for treatment
             by NCI Working Group Criteria: or (b) Rai stage III or IV.

          -  Received a minimum of one prior chemotherapy regimen. Prior treatment with
             corticosteroids, immunotherapies, monoclonal antibodies or radiation therapy is
             permitted.

          -  White blood cell count &gt; 25 x 10^9/L

          -  ECOG 0, 1,or 2.

          -  Adequate renal and hepatic function

          -  Platelets &gt; 75 x 10^9/L, transfusion independent.

          -  Neutrophils &gt; 1.0 x 10^9/L, transfusion independent

        Exclusion Criteria:

          -  Documented prolymphocytic leukemia (PLL; prolymphocytes, 55% in blood)

          -  Active cardiovascular disease as defined by NYHA class III-IV categorization.

          -  Intercurrent illness or medical condition precluding safe administration of ribavirin.

          -  Concurrent use of chronic steroids, except as replacement therapy for adrenal
             insufficiency

          -  Known infection with HIV, Hepatitis B or C.

          -  Concurrent malignancy (other than resected basal or squamous cell skin cancers or
             in-situ carcinoma).

          -  Received any previous therapy for CLL within 28 days prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarit Assouline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Panasci, MD</last_name>
    <role>Study Director</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles Lemoyne Hospital</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia. 2004 Mar;18(3):409-14.</citation>
    <PMID>14712290</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>April 14, 2010</last_update_submitted>
  <last_update_submitted_qc>April 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <keyword>CLL</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>leukemia</keyword>
  <keyword>gleevec</keyword>
  <keyword>chlorambucil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

